Eli Lilly Touts Strong Results of New Experimental Weight Loss Drug Retatrutide

Eli Lilly touts strong results of new experimental weight loss drug retatrutide

Move over Ozempic, Wegovy, Mounjaro and Zepbound — Eli Lilly says another contender may be on the way. The pharmaceutical giant announced encouraging results from a Phase 3 clinical trial of its experimental weight loss drug retatrutide, showing levels of weight loss that could rival — or exceed — existing blockbuster treatments. What the study found According to Eli Lilly, patients taking retatrutide lost nearly 30% of their body weight over 68…

People Are Already Taking This Unapproved New Weight-Loss Drug

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still haven’t finished.

New weight loss drug dubbed 'triple G' shows promise: What to know about retatrutide

Retatrutide works by mimicking three hunger-regulating hormones.

Eli Lilly shot helped patients lose 29% of body weight

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight

An experimental obesity drug called retatrutide that targets GLP-1 and two other hormones helped people lose nearly one-third of their starting body weight, on average, in a late-stage clinical trial. These results, according to drugmaker Lilly, suggest retatrutide may be more powerful than other injectable obesity drugs like Wegovy or Zepbound .e60dc2a1-f33c-4a05-9b50-8e3e8e597629d08cc4e7-3e87-4d07-b6dd-186c328f6524 The trial included 445 adult…

Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.The post Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial appeared first on Clinical Trials Arena.